Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015 (2015), Article ID 369465, 7 pages
http://dx.doi.org/10.1155/2015/369465
Clinical Study

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

1Institute of Neurology, IRCCS San Raffaele, Via della Pisana 235, 00163 Rome, Italy
2Vernalis (R&D) Ltd., Reading Road, Winnersh, Berkshire RG41 5UA, UK
3Chiesi Farmaceutici SpA, 43100 Parma, Italy

Received 12 March 2015; Revised 5 May 2015; Accepted 18 May 2015

Academic Editor: Jan O. Aasly

Copyright © 2015 Fabrizio Stocchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. W. Olanow, Y. Agid, Y. Mizuno et al., “Levodopa in the treatment of Parkinson's disease: current controversies,” Movement Disorders, vol. 19, no. 9, pp. 997–1005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. C. D. Marsden and J. D. Parkes, “Success and problems of long term levodopa therapy in Parkinson's disease,” The Lancet, vol. 1, no. 8007, pp. 345–349, 1977. View at Google Scholar · View at Scopus
  3. E. Miyawaki, K. Lyons, R. Pahwa et al., “Motor complications of chronic levodopa therapy in Parkinson's disease,” Clinical Neuropharmacology, vol. 20, no. 6, pp. 523–530, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Stocchi, “Prevention and treatment of motor fluctuations,” Parkinsonism and Related Disorders, vol. 9, supplement 2, pp. S73–S81, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Stocchi, “The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations,” Expert Opinion on Pharmacotherapy, vol. 7, no. 10, pp. 1399–1407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. Nutt, “On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics,” Annals of Neurology, vol. 22, no. 4, pp. 535–540, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Melamed, V. Bitton, and O. Zelig, “Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators,” Neurology, vol. 36, no. 1, pp. 100–103, 1986. View at Publisher · View at Google Scholar · View at Scopus
  8. J. G. Nutt, W. R. Woodward, J. P. Hammerstad, J. H. Carter, and J. L. Anderson, “The ‘on-off’ phenomenon in Parkinson's disease. Relation to levodopa absorption and transport,” The New England Journal of Medicine, vol. 310, no. 8, pp. 483–488, 1984. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Contin and P. Martinelli, “Pharmacokinetics of levodopa,” Journal of Neurology, vol. 257, supplement 2, pp. 253–261, 2010. View at Publisher · View at Google Scholar
  10. P. Chaná, C. Kuntsmann, M. Reyes-Parada, and P. Sáez-Briones, “Delayed early morning turn ‘ON’ in response to a single dose of levodopa in advanced Parkinson's disease: Pharmacokinetics should be considered,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 12, pp. 1782–1783, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Cersosimo and E. E. Benarroch, “Neural control of the gastrointestinal tract: implications for Parkinson disease,” Movement Disorders, vol. 23, no. 8, pp. 1065–1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Djaldetti, J. Baron, I. Ziv, and E. Melamed, “Gastric emptying in Parkinson's disease: patients with and without response fluctuations,” Neurology, vol. 46, no. 4, pp. 1051–1054, 1996. View at Google Scholar · View at Scopus
  13. R. Kurlan, K. P. Rothfield, W. R. Woodward et al., “Erratic gastric emptying of levodopa may cause ‘random’ fluctuations of parkinsonian mobility,” Neurology, vol. 38, no. 3, pp. 419–421, 1988. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Nyholm, “Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update,” Clinical Pharmacokinetics, vol. 45, no. 2, pp. 109–136, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. C. Kurth, J. W. Tetrud, I. Irwin, W. H. Lyness, and J. W. Langston, “Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study,” Neurology, vol. 43, no. 5, pp. 1036–1039, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Stocchi, S. Ruggieri, A. Carta, P. Jenner, and A. Agnoli, “Different therapeutic approaches in Parkinson’s disease. Clinical, pharmacological and physiological aspects,” in Disorders of Movements, N. F. Quinn and P. G. Jenner, Eds., pp. 137–146, Academic Press, London, UK, 1989. View at Google Scholar
  17. F. Stocchi, L. Fabbri, L. Vecsei, A. Krygowska-Wajs, P. A. Monici Preti, and S. A. Ruggieri, “Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease,” Clinical Neuropharmacology, vol. 30, no. 1, pp. 18–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Rondelli, D. Acerbi, F. Mariotti, and P. Ventura, “Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection,” Journal of Chromatography B: Biomedical Applications, vol. 653, no. 1, pp. 17–23, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Vickers, C. A. Duncan, S. D. White et al., “Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog and rat,” Drug Metabolism and Disposition, vol. 6, no. 6, pp. 640–646, 1978. View at Google Scholar · View at Scopus
  20. K. Sasahara, T. Nitanai, T. Habara, T. Morioka, and E. Nakajima, “Dosage form design for improvement of bioavailability of levodopa III: influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients,” Journal of Pharmaceutical Sciences, vol. 69, no. 12, pp. 1374–1378, 1980. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Steiger, F. Stocchi, L. Bramante, S. Ruggieri, and N. P. Quinn, “The clinical efficacy of single morning doses of levodopa methyl ester: Dispersible Madopar and Sinemet plus in Parkinson disease,” Clinical Neuropharmacology, vol. 15, no. 6, pp. 501–504, 1992. View at Google Scholar · View at Scopus
  22. F. Stocchi, L. Barbato, L. Bramante, A. Bonamartini, and S. Ruggieri, “The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo,” Functional Neurology, vol. 9, no. 5, pp. 259–264, 1994. View at Google Scholar · View at Scopus
  23. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progression and mortality,” Neurology, vol. 17, no. 5, pp. 427–442, 1967. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Heikkinen, A. Varhe, T. Laine et al., “Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose,” British Journal of Clinical Pharmacology, vol. 54, no. 4, pp. 363–371, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. C. D. Marsden, “Parkinson's disease,” The Lancet, vol. 335, no. 8695, pp. 948–952, 1990. View at Google Scholar · View at Scopus
  27. F. Silva, “Effects of CHF 1512, a new combination of levodopa methylester and carbidopa, on motor fluctuations in Parkinson's disease: results from a European study,” Movement Disorders, vol. 21, supplement 13, pp. S119–S120, 2006. View at Google Scholar